Gastrointestinal stromal tumors, version 2.2014: Featured updates to the NCCN Guidelines

Margaret Von Mehren; R. Lor Randall; Robert S. Benjamin; Sarah Boles; Marilyn M. Bui; Ephraim S. Casper; Ernest U. Conrad; Thomas F. DeLaney; Kristen N. Ganjoo; Suzanne George; Ricardo J. Gonzalez; Martin J. Heslin; John M. Kane; Joel Mayerson; Sean V. McGarry; Christian Meyer; Richard J. O'Donnell; Alberto S. Pappo; I. Benjamin Paz; John D. Pfeifer; Richard F. Riedel; Scott Schuetze; Karen D. Schupak; Herbert S. Schwartz; Brian A. Van Tine; Jeffrey D. Wayne; Mary Anne Bergman; Hema Sundar

doi:10.6004/jnccn.2014.0080

Gastrointestinal stromal tumors, version 2.2014: Featured updates to the NCCN Guidelines

Margaret Von Mehren
, R. Lor Randall
, Robert S. Benjamin
, Sarah Boles
, Marilyn M. Bui
, Ephraim S. Casper
, Ernest U. Conrad
, Thomas F. DeLaney
, Kristen N. Ganjoo
, Suzanne George
, Ricardo J. Gonzalez
, Martin J. Heslin
, John M. Kane
, Joel Mayerson
, Sean V. McGarry
, Christian Meyer
, Richard J. O'Donnell
, Alberto S. Pappo
, I. Benjamin Paz
, John D. Pfeifer

Richard F. Riedel, Scott Schuetze, Karen D. Schupak, Herbert S. Schwartz, Brian A. Van Tine, Jeffrey D. Wayne, Mary Anne Bergman, Hema Sundar

Research output: Contribution to journal › Article › peer-review

112 Scopus citations

Abstract

Gastrointestinal stromal tumors (GIST) are the most common soft tissue sarcoma of the gastrointestinal tract, resulting most commonly from KIT or platelet-derived growth factor receptor α (PDGFRα)-activating mutations. These NCCN Guideline Insights high-light the important updates to the NCCN Guidelines for Soft Tissue Sarcoma specific to the management of patients with GIST experiencing disease progression while on imatinib and/or sunitinib.

Original language	English
Pages (from-to)	853-862
Number of pages	10
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	12
Issue number	6
DOIs	https://doi.org/10.6004/jnccn.2014.0080
State	Published - Jun 1 2014

Access to Document

10.6004/jnccn.2014.0080

Cite this

Von Mehren, M., Randall, R. L., Benjamin, R. S., Boles, S., Bui, M. M., Casper, E. S., Conrad, E. U., DeLaney, T. F., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., Kane, J. M., Mayerson, J., McGarry, S. V., Meyer, C., O'Donnell, R. J., Pappo, A. S., Paz, I. B., ... Sundar, H. (2014). Gastrointestinal stromal tumors, version 2.2014: Featured updates to the NCCN Guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 12(6), 853-862. https://doi.org/10.6004/jnccn.2014.0080

@article{529ddcb755634dceb38409932a08ea17,

title = "Gastrointestinal stromal tumors, version 2.2014: Featured updates to the NCCN Guidelines",

abstract = "Gastrointestinal stromal tumors (GIST) are the most common soft tissue sarcoma of the gastrointestinal tract, resulting most commonly from KIT or platelet-derived growth factor receptor α (PDGFRα)-activating mutations. These NCCN Guideline Insights high-light the important updates to the NCCN Guidelines for Soft Tissue Sarcoma specific to the management of patients with GIST experiencing disease progression while on imatinib and/or sunitinib.",

author = "\{Von Mehren\}, Margaret and Randall, \{R. Lor\} and Benjamin, \{Robert S.\} and Sarah Boles and Bui, \{Marilyn M.\} and Casper, \{Ephraim S.\} and Conrad, \{Ernest U.\} and DeLaney, \{Thomas F.\} and Ganjoo, \{Kristen N.\} and Suzanne George and Gonzalez, \{Ricardo J.\} and Heslin, \{Martin J.\} and Kane, \{John M.\} and Joel Mayerson and McGarry, \{Sean V.\} and Christian Meyer and O'Donnell, \{Richard J.\} and Pappo, \{Alberto S.\} and Paz, \{I. Benjamin\} and Pfeifer, \{John D.\} and Riedel, \{Richard F.\} and Scott Schuetze and Schupak, \{Karen D.\} and Schwartz, \{Herbert S.\} and \{Van Tine\}, \{Brian A.\} and Wayne, \{Jeffrey D.\} and Bergman, \{Mary Anne\} and Hema Sundar",

year = "2014",

month = jun,

day = "1",

doi = "10.6004/jnccn.2014.0080",

language = "English",

volume = "12",

pages = "853--862",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

number = "6",

}

Von Mehren, M, Randall, RL, Benjamin, RS, Boles, S, Bui, MM, Casper, ES, Conrad, EU, DeLaney, TF, Ganjoo, KN, George, S, Gonzalez, RJ, Heslin, MJ, Kane, JM, Mayerson, J, McGarry, SV, Meyer, C, O'Donnell, RJ, Pappo, AS, Paz, IB, Pfeifer, JD, Riedel, RF, Schuetze, S, Schupak, KD, Schwartz, HS, Van Tine, BA, Wayne, JD, Bergman, MA & Sundar, H 2014, 'Gastrointestinal stromal tumors, version 2.2014: Featured updates to the NCCN Guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 12, no. 6, pp. 853-862. https://doi.org/10.6004/jnccn.2014.0080

TY - JOUR

T1 - Gastrointestinal stromal tumors, version 2.2014

T2 - Featured updates to the NCCN Guidelines

AU - Von Mehren, Margaret

AU - Randall, R. Lor

AU - Benjamin, Robert S.

AU - Boles, Sarah

AU - Bui, Marilyn M.

AU - Casper, Ephraim S.

AU - Conrad, Ernest U.

AU - DeLaney, Thomas F.

AU - Ganjoo, Kristen N.

AU - George, Suzanne

AU - Gonzalez, Ricardo J.

AU - Heslin, Martin J.

AU - Kane, John M.

AU - Mayerson, Joel

AU - McGarry, Sean V.

AU - Meyer, Christian

AU - O'Donnell, Richard J.

AU - Pappo, Alberto S.

AU - Paz, I. Benjamin

AU - Pfeifer, John D.

AU - Riedel, Richard F.

AU - Schuetze, Scott

AU - Schupak, Karen D.

AU - Schwartz, Herbert S.

AU - Van Tine, Brian A.

AU - Wayne, Jeffrey D.

AU - Bergman, Mary Anne

AU - Sundar, Hema

PY - 2014/6/1

Y1 - 2014/6/1

N2 - Gastrointestinal stromal tumors (GIST) are the most common soft tissue sarcoma of the gastrointestinal tract, resulting most commonly from KIT or platelet-derived growth factor receptor α (PDGFRα)-activating mutations. These NCCN Guideline Insights high-light the important updates to the NCCN Guidelines for Soft Tissue Sarcoma specific to the management of patients with GIST experiencing disease progression while on imatinib and/or sunitinib.

AB - Gastrointestinal stromal tumors (GIST) are the most common soft tissue sarcoma of the gastrointestinal tract, resulting most commonly from KIT or platelet-derived growth factor receptor α (PDGFRα)-activating mutations. These NCCN Guideline Insights high-light the important updates to the NCCN Guidelines for Soft Tissue Sarcoma specific to the management of patients with GIST experiencing disease progression while on imatinib and/or sunitinib.

UR - https://www.scopus.com/pages/publications/84902515659

U2 - 10.6004/jnccn.2014.0080

DO - 10.6004/jnccn.2014.0080

M3 - Article

C2 - 24925196

AN - SCOPUS:84902515659

SN - 1540-1405

VL - 12

SP - 853

EP - 862

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 6

ER -

Gastrointestinal stromal tumors, version 2.2014: Featured updates to the NCCN Guidelines

Abstract

Access to Document

Other files and links

Fingerprint

Cite this